We are a science-driven biopharmaceutical company developing novel nicotine-blocking therapies to treat diseases caused or worsened by nicotine.

Our initial development strategy of treating existing disease to improve medical outcomes – rather than preventing future smoking-related illnesses that may occur decades later – is significantly different from how other drugs that target nicotine’s actions have been developed as aids to smoking cessation.

The first indications for Antidote’s anti-nicotine drugs are the treatment of orphan vascular diseases in smokers where nicotine plays an important role in causing disease progression, such as Buerger’s Disease and Critical Limb Ischemia. Buerger’s disease is a serious medical condition requiring new treatment approaches, and as an orphan disease, it should support accelerated development and market availability. Our products, which neutralize nicotine’s direct cardiovascular effects, may also help patients quit or substantially reduce smoking. This is expected to lead to better overall treatment outcomes across all vascular disease patients.

At Antidote Therapeutics, we have built a world-class collaborative drug research and development team of renowned experts, academic researchers, clinicians, consultants and advisors to address nicotine’s harmful and addictive effects. We are developing two first-in-class nicotine-blocking therapeutics:

  • Fully human, anti-nicotine monoclonal antibody
  • Nicotine-degrading enzyme

Unlike FDA-approved smoking cessation treatments, our candidates do not contain nicotine or interact with nicotine-receptors in the brain or body. Instead, our anti-nicotine therapeutics are designed to trap or eliminate nicotine in the blood, having the dual benefit of neutralizing nicotine’s direct, harmful effects on organs throughout the body and preventing nicotine from reaching the brain, thereby reducing the addictiveness of nicotine from cigarettes, e-cigarettes, and smokeless tobacco.

In the future, we plan to expand the uses of our products to other smoking-related illnesses where blocking nicotine’s effects will have near-term medical benefit as well as a general aid to smoking cessation.